BRAF and neoplasm: Ishimura and co-workers reported concomitant K-RAS and BRAF activating mutations in tumor samples [50], with no clinicopathological incidence as compared to K-RAS mutation alone, suggesting that there is no cumulative effect and that the addition of the two mutations is not an advantage for tumor progression.